A major obstacle to the effective use of adoptive immunotherapeutic treatment of cancer is the difficulty of obtaining tumor-reactive lymphocytes in either sufficient numbers or with appropriate in vivo function to make such an approach feasible. Previous studies have shown that antitumor cytotoxic T lymphocytes (CTL) with in vivo efficacy can be generated in vitro from lymphoid cells obtained from lymph nodes that drain the anatomical site of a tumor. Results presented here demonstrate that inclusion of interleukin 7 (IL-7) into the medium in which such CTL are cultured can support their growth in vitro for prolonged periods of time in the absence of repeated stimulation with either tumor stimulator cells or tumor antigen. More importantly, antitumor CTL propagated in medium containing IL-7 have retained both their antigenic specificity and their ability to reject tumors in vivo subsequent to intravenous injection. Parallel cultures of antitumor CTL similarly cultured in medium containing only IL-2 could only be maintained for 5-6 wk, after which the number and proportion of viable cells that were recoverable from such cultures progressively decreased. Phenotypic analysis of CTL maintained after extended culture (i.e., 22 mo) in medium containing IL-7 demonstrated them to be CD3+4-8 § T cells. These cells were also found to express lymphocyte function associated 1, intercellular adhesion molecule 1, and Mel-14 cell interaction molecules. The data also demonstrate that these CTL do not require the presence of antigen-presenting cell populations to mount a proliferative response to tumor stimulator cells. Cells in these cultures were also demonstrated to produce IL-2 after stimulation with irradiated tumor cells, thereby indicating that these CTL have become independent of the requirement for CD4 § helper cells to survive and function either in vitro or in vivo. Collectively, the findings that IL-7 can beneficially augment the generation, and propagate the long-term growth, of antitumor CTL from lymph nodes draining a tumor site may have profound implications for promoting the immunotherapeutic treatment of cancer in humans.
Summary
A major obstacle to the effective use of adoptive immunotherapeutic treatment of cancer is the difficulty of obtaining tumor-reactive lymphocytes in either sufficient numbers or with appropriate in vivo function to make such an approach feasible. Previous studies have shown that antitumor cytotoxic T lymphocytes (CTL) with in vivo efficacy can be generated in vitro from lymphoid cells obtained from lymph nodes that drain the anatomical site of a tumor. Results presented here demonstrate that inclusion of interleukin 7 (IL-7) into the medium in which such CTL are cultured can support their growth in vitro for prolonged periods of time in the absence of repeated stimulation with either tumor stimulator cells or tumor antigen. More importantly, antitumor CTL propagated in medium containing IL-7 have retained both their antigenic specificity and their ability to reject tumors in vivo subsequent to intravenous injection. Parallel cultures of antitumor CTL similarly cultured in medium containing only IL-2 could only be maintained for 5-6 wk, after which the number and proportion of viable cells that were recoverable from such cultures progressively decreased. Phenotypic analysis of CTL maintained after extended culture (i.e., 22 mo) in medium containing IL-7 demonstrated them to be CD3+4-8 § T cells. These cells were also found to express lymphocyte function associated 1, intercellular adhesion molecule 1, and Mel-14 cell interaction molecules. The data also demonstrate that these CTL do not require the presence of antigen-presenting cell populations to mount a proliferative response to tumor stimulator cells. Cells in these cultures were also demonstrated to produce IL-2 after stimulation with irradiated tumor cells, thereby indicating that these CTL have become independent of the requirement for CD4 § helper cells to survive and function either in vitro or in vivo. Collectively, the findings that IL-7 can beneficially augment the generation, and propagate the long-term growth, of antitumor CTL from lymph nodes draining a tumor site may have profound implications for promoting the immunotherapeutic treatment of cancer in humans.
A major obstacle to the effective use of adoptive immunotherapeutic treatment of cancer is the difficulty of obtaining tumor-reactive lymphocytes in either sufficient numbers or with appropriate in vivo function to make such an approach feasible. Experimental attempts in murine systems to solve these problems have included the use of donors actively immunized with either irradiated tumor cells or tumor cells mixed with potent adjuvants as sources of primed tumorreactive lymphoid cells for expansion in vitro (1) (2) (3) (4) (5) (6) (7) (8) (9) . However, in the human situation, the luxury of syngeneic donors who can be immunized and from whom tumor-reactive T cells can be obtained and propagated for subsequent immunotherapeutic use does not exist.
The observation that solid tumor masses are often infiltrated by T cells (10) (11) (12) suggested the possibility that such tumorinfiltrating lymphocytes (TIL) 1 might be enriched for tumor-reactive T cells that could be expanded in vitro using recombinant cytokines such as IL-2 (13) (14) (15) (16) (17) (18) . However, even short-term culture of tumor-reactive T cells in growthpromoting concentrations of IL-2 enhances the generation ofT cells that are dependent upon exogenous IL-2 for growth and survival in vitro and optimal function in vivo. Results from several studies have demonstrated the need for continuing treatment of the recipients with IL-2 after the infusion of antitumor effector cells in order to promote optimal function in vivo (7, 8, (19) (20) (21) (22) . As has previously been shown, administration of doses of IL-2 sufficient to maintain proliferation and effector function of transferred TIL can lead to significant toxicity. Further, even when using cultured TIL as a source of tumor-reactive lymphocytes it has been estimated that >2 x 1011 cells would be required to effectively treat patients with metastatic disease (23) . These deficiencies continue to provide a major impetus for the development of techniques to enhance the in vivo efficacy of antitumor CTL generated in vitro.
LN that drain the anatomical site of a tumor contain increased numbers of lymphocytes, and these cells can differentiate into antitumor CTL during a short in vitro culture period (24, 25) . We have previously demonstrated that intravenous injection of relatively modest numbers of antitumor CTL generated from such draining lymph nodes (DLN) are able to mediate tumor rejection in a systemic fashion and do not require ancillary cytokine treatment in order to perform this function (26) . In addition, we have recently evaluated the effects of a number of cytokines and combinations of cytokines to augment the generation of therapeutically effective antitumor CTL from these DLN. In this regard, IL-7 was demonstrated to be substantially more potent than either IL-2 or IL-4 (27) .
During the course of these studies we noted that addition of IL-7 to culture medium promoted the long-term growth and maintenance of antitumor CTL in vitro. The studies presented here were performed to characterize the CTL maintained in vitro for extended periods of time under such conditions and to evaluate their potential use in the immunotherapeutic treatment of cancer. The results dearly demonstrate that antitumor CTL can be maintained in vitro for prolonged periods of time in the absence of repeated stimulation with either tumor-stimulator cells or tumor antigen. More importantly, antitumor CTL propagated in medium containing IL-7 retain both their antigenic specificity and their ability to reject tumors in vivo subsequent to intravenous injection.
Materials and Methods
Mice. Female C57BL/10J mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were age-matched (10-12-wkold) at the onset of each experiment. Tumors. B10.2 and B10.5 are fibrosarcomas of B10 origin and have been described previously (26, 27) . Tumor cell lines were maintained in vitro in c~-modified MEM containing 5% FBS, 2 mM glutamine, 50 U/ml penicillin, and 50/~g/ml streptomycin. The cultures of tumor cells were routinely screened for the presence of mycoplasma using a detection system (Genprobe, San Diego, CA), and determined to be mycoplasma free.
Tumor Immunization and Generation of Antitumor CTL. Mice were injected in the hind footpads with 2-4 x 106 viable syngeneic tumor cells. DLN were aseptically excised 8-12 d later and dissociated into a single cell suspension. Cell cultures were established (in the absence of added tumor stimulator cells) in upright 25 cm 2 tissue culture flasks at 1.5 x 106 viable cells/ml (20 ml/flask) in RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 5 x 10 -5 M 2-ME, 50 #g/ml streptomycin, and 50 U/ml penicillin at 37~ in a humidified atmosphere of 5% CO2 in air. After 4 d in culture, the resulting CTL were subcultured in 24-well tissue culture plates at a concentration of 5 x 105 cells/ml (2 ml/well) in medium supplemented with IL-2 (5 ng/ml), IL-7 (10 ng/ml), or a mixture of IL-2 and IL-7 (2 and 10 ng/ml, respectively) with irradiated (10,000 rad) tumor stimulator cells. Unless otherwise noted, the subcultures were then maintained by weekly feeding with the appropriate medium in the absence of additional tumor cell stimulation. 
Results

In Vitro and In Vivo Function of Antitumor CTL Propagated in Cytokine-containing Medium.
To determine whether an-titumor CTL could be maintained for extended periods of time in vitro in cytokine-containing media, lymphocytes from cultures of B10 anti-B10.5 DLN were recovered and recultured with irradiated tumor stimulator cells in either medium alone or medium containing IL-2, IL-7, or a combination of IL-2 and IL-7 (106 cells/culture). These cultures were subsequently passaged every 7-10 d in the appropriate medium in the the absence of further stimulation with irradiated tumor cells. Although the numbers of cells in all of the culture groups increased from the initial 106 cells during the first week after restimulation, after 25 d the total number of viable cells recovered from cultures of cells maintained in medium alone had decreased to <3 x 104. The number of cells recovered from cultures maintained in IL-2 had increased to 2 x 106 and cells cultured in IL-7 or IL-2 and IL-7 had increased to 8 • 106 and 11 x 106, respectively. After the removal of 106 cells from each of these cultures for assessment of tumoricidal activity in vitro (discussed below), cultures of the remaining cells were maintained in fresh media containing the appropriate cytokine(s). After an additional 7 d of culture, CTL grown in IL-2 increased from 106 tO 5.6 x 106 cells, CTL grown in IL-7 increased from 7.0 x 106 to 17.5 x 106 cells, and CTL cultured in a combination of IL-2 and IL-7 increased from 10 x 106 to 32 x 106 cells. Thereafter, cells from cultures maintained in IL-2 decreased in both total number and viability until <(106 were recoverable by day 60 of culture. In contrast, CTL cultured in either IL-7 alone or a combination of IL-2 and IL-7 slowly increased during this time period with average doubling times of 5-6 d.
Analysis of effector cell function of the CTL maintained in vitro for either 25, 32, or 53 d after their initiation demonstrated potent and specific tumoricidal activity in vitro ( Fig.  1 , A, B, and C, respectively). Flow cytometric analysis of these three cell populations at day 32 of culture revealed similar profiles in which 100% of the cells were Thy 1.2 +, CD3 + T cells (Fig. 2 ). Of these, 95% were CD8 + and ~3-4% were CD4 + .
The ability of these populations of CTL to mediate tumor rejection in vivo was initially tested on day 32 of culture by intravenously injecting 2 x 10 6 antitumor CTL maintained in either IL-7 or IL-2 and IL-7 into 500 rad irradiated recipients, followed by bilateral tumor challenge with B10.5 and B10.2 tumor cells. Recoveries of cells from cultures maintained in IL-2 alone were too low to permit functional assessment in vivo. Mice that received anti-B10.5 CTL maintained in either IL-7 alone or a combination of IL-2 and IL-7 effectively rejected challenges orB10.5 tumor cells, but not B10.2 tumor cells (Fig. 3 A) . Growth of the B10.2 tumor challenge cannot be ascribed to an inherent inability of this tumor to be rejected because B10.2 tumor cells were eliminated by anti-B10.2 CTL freshly generated from cultures of B10 anti-B10.2 DLN cells (Fig. 3 B) .
During the course of these experiments we noted that the tumoricidal activity of the anti-B10.5 CTL slowly decreased as a function of increasing time in culture. For example, the lyric activity of CTL maintained in IL-2 and IL-7 could not be determined at day 25 (because plateau-level killing of target cells was observed even at the lowest E/T ratio tested), whereas 33 Lynch and Miller 
Effects of Cytoleines and Tumor Stimulator Cells on Proliferative Responses ofAntitumor CTL.
We next sought to determine the effect of various cytokines in the presence or absence of irradiated tumor stimulator cells on the proliferation of CTL grown for 5 mo in vitro 9 Culture of CTL in medium containing IL-2 caused increased levels of [3H]TdR incorporation compared with CTL cultured in the medium alone, and substantially increased the levels of [3H]TdR incorporation by the antitumor CTL in the presence of tumor stimulator cells compared with that induced by tumor stimulator cells alone (Table 1) . A slight increase in the proliferative response induced by B10.5 tumor stimulator cells was detected in cultures to which IL-4 had been added, suggesting that IL-4 could also act as a costimulatory molecule for antigenspecific stimulation of these cells. However, no direct stimulatory effect of IL-4 on these CTL was detected and dose-response studies have indicated that the costimulatory effect of IL-4 is ",50-fold weaker than that mediated by IL-2 (data not shown). None of the other cytokines tested, including IL-7, led to significant increases in proliferation over that seen in the presence of medium alone.
In Vivo Ej~cacy of Antitumor CTL Maintained in Medium Containing IL-2 and IL-7.
To determine the efficacy of antitumor CTL maintained in culture for extended periods of time, CTL that had been maintained in vitro in the absence of tumor cell stimulation for 6 mo were intravenously injected into 500 rad mice that were intradermally challenged with B10.5 tumor cells. In this experiment, intravenous injection of even the lowest number of CTL tested (105) was sufficient to mediate complete elimination of the tumor chal- Table 2 ). The mice in each of the treatment groups that received the antitumor CTL were monitored for an additional 138 d after the termination of the experiment and found to be completely free of detectable tumors.
A similar experiment was performed using B10 anti-B10.2 CTL that had been maintained in vitro for 7 mo in the absence of tumor cell restimulation (Fig. 5) . In this experiment, the intradermal challenge of B10.2 cells was completely rejected in all mice that received either 3 x 106 anti-B10.2 CTL. Although small tumors were detected during the first week after tumor challenge in three of the four mice that received 106 CTL, they were all found to be tumor free by day 13. The tumor challenge also grew transiently in all four of the mice that received 3 x 10 s CTL. However, the tumors were ultimately rejected in three of the four mice in this group, and grew more slowly in the 4th mouse compared with controls. progressive tumor growth was observed in all of the mice challenged in this group.
Antitumor CTL Maintained Long-Term in Medium Containing IL-2 and IL-7 Mediate Tumor Rejection In Vivo. Although it
had been determined that CTL cultured for relatively short (2-6 mo) periods of time could mediate tumor rejection in vivo, it was not known whether this function would be gradually lost as a function of time in culture in the absence of specific stimulation with tumor antigen. Thus, the ability of these CTL to mediate tumor rejection in vivo was tested at various times by intravenously injecting 500 rad-irradiated mice with CTL that had been maintained under a variety of conditions followed by an intradermal challenge with B10.5 tumor ceUs. antitumor cytotoxic activity of these CTL was also measured using a 51Cr-release assay. Not only were antitumor CTL from cultures that had been restimulated with tumor antigen at various times during their culture history able to specifically eliminate a tumor challenge in vivo, but so were CTL that had been maintained in continuous culture in the absence of tumor stimulation for as long as 31 mo (Table 3) . The data also demonstrate that cryogenic storage of these cells does not result in loss of ability to mediate tumor rejection in a systemic fashion. Interestingly, the in vitro cytotoxic activity of the cell lines tested was not predictive of their ability to mediate tumor rejection in vivo since cells without detectable tumoricidal activity in short-term in vitro assays were still able to mediate tumor rejection in vivo.
Proliferation of CTL to Tumor Stimulator Cells Is Dependent on Endogenously Produced IL-2.
The ability of antitumor CTL maintained in medium containing IL-2 and IL-7 to proliferate in response to stimulation by tumor cells was evaluated by culture of these CTL in the presence of medium alone or irradiated B10.5 tumor cells, in the presence of either $4B6 (anti-IL-2), 11Bll (anti-IL-4), or a combination of S4B6 and 11Bll Abs. Proliferative responses of these CTL to stimulation with B10.5 tumor cells was inhibited with anti-IL-2, but not anti-IL-4, Abs (Fig. 6) . Nor was the inhibitory effect mediated by the anti-IL-2 Abs enhanced by addition of anti-IL-4 Abs. Thus, the proliferative responses induced in these CTL are dependent upon endogenously produced IL-2. Further, although IL-4 can act as a cofactor to promote proliferative responses induced by tumor-stimulator cells, its presence is neither required nor sufficient.
Kinetics of Cytokine Production after Stimulation with Tumor
Cells In Vitro. Anti-B10.5 CTL maintained in culture for 23 mo in medium containing IL-2 and IL-7 were cultured either alone or with irradiated B10.5 or B10.2 stimulator cells. Culture supernatants from replicate wells were harvested 24, 48, 72, or 96 h after culture initiation. Analysis of cytokines present in the supernatants revealed significant levels of IL-2 produced by CTL stimulated with B10.5 tumor cells during the first 24 h (Fig. 7 A) . Lower levels of IL-2 were also detected in supernatants collected after 48 h of culture, but not after 72 or 96 h, suggesting that the IL-2 being produced was also being consumed by the CTL. This interpretation is consistent with the finding that anti-IL-2 Abs completely inhibited the proliferative response of the CTL to B10.5 stimulator cells. The possibility that the IL-2 detected in these supernatants was produced by CD4 + cells is not supported since no CD4 + cells could be detected by FACS | analysis. Nor was IL-2 detected in supernatants from CTL cultured either in medium alone or with B10.2 stimulator cells.
High levels of IFN-y were also produced by the CTL after stimulation with B10.5, but not B10.2, tumor cells (Fig. 7  B) . In contrast to the situation observed with IL-2 production, however, the levels of IFN-9/detected remained relatively high throughout the course of the experiment. Thus, either the IFN-9/produced was not consumed to any significant degree by the CTL or the CTL continued to produce this cytokine for extended periods of time after stimulation with the B10.5 tumor cells. As with IL-2, no production of IFN-9/ was detected in cultures of CTL cultured with B10.2 tumor cells or in medium alone. No IL-4 or TNF-oe was detected in supernatants from CTL cultured with either B10.5 or B10.2 stimulator cells at any of the time points tested.
Flow Cytometric Analysis of Antitumor CTL Maintained LongTerm in Medium Containing 11_.-7. Flow microfluorometric
analysis of anti-B10.5 CTL maintained for 22 mo in medium containing IL-2 and IL-7 determined them to be CD3+4-8 + T cells expressing TCR-oe/3, but not TCR-9//8, receptors (Fig. 8) . These CTL also express CD-44, ICAM-1, LFA-1, and Mel-14, but not HSA, cell surface determinants. Low levels of IL-2R (a chain) were also found to be expressed by the majority of these cells. Thus, the data regarding the cell surface phenotype of the antitumor CTL maintained in medium containing IL-7 are consistent with these cells being mature memory cells with the ability to traffic through, and extravasate from, the vasculature at the site of a tumor challenge. . Finally, to determine whether The results not only demonstrate that tumor-specific CTL can be maintained in vitro in IL-7, but that repeated restimulation of the cells is not necessary for their maintenance. Parallel cultures of antitumor CTL similarly cultured in medium containing only IL-2 could only be maintained for 5-6 wk, after which the number and proportion of viable cells that were recoverable from such cultures progressively decreased. In contrast, cell cultured in either IL-7 or a combination of IL-2 and IL-7 grew at a slower pace, yet cell viability remained consistently high (>98%). Further, these CTL maintained the ability to specifically proliferate upon stimulation with tumor cells. More importantly, the effector cells were able to effectively reject tumor challenges in vivo in a systemic fashion after intravenous injection. The lytic activity of antitumor CTL maintained in culture with IL-7 was found to slowly decrease as a function of increasing time in culture. Although the reasons for this phenomenon are not understood, a substantial increase in tumoricidal activity was detected after a short in vitro restimulation of the CTL with tumor cells (Fig. 4) . The in vitro cytolytic activity of CTL cultured for extended periods of time (i.e., 11-31 mo) was also found to be somewhat variable (Table 3) . However, the data also clearly indicate that the cytolytic activity of effector cell populations cannot be used as reliable predictors of in vivo ef~cacy, since cells with no apparent cytotoxic activity (as measured in a short-term SlCrrelease assay) were still able to mediate tumor rejection in vivo. This observation is in agreement with the results of previous studies by both ourselves (27) and others (21) who have demonstrated that in vitro assays of tumoricidal activity cannot be used as reliable predictors of therapeutic activity in vivo.
Elimination of Established Tumors by CTL Maintained In Vitro in Medium Containing
Early in their culture history (ca 6 wk) a small percentage of the ceils were found to be CD4 +, although the vast majority (95%) were identified as CD8 + T ceils. This led to the early speculation that the CD4 + T cells might actually be tumor-specific helper cells that were required to promote the propagation of the antitumor CTL. However, phenotypic analysis of the CTL after extended culture (i.e., 22 too) demonstrated them to be uniformly CD3+4-8 + T cells. These cells were also found to express LFA-1, ICAM-1, and Mel-14 cell interaction molecules. These determinants no doubt play an integral role in the ability of the CTL to traf~c through the circulation to the site of an intradermal tumor challenge to mediate tumor rejection.
It is also of interest to note that these CTL do not require the presence of APC populations to process and present tumor antigen to the CTL, indicating that the CTL recognize a tumor-specific antigen on the surface of the tumor ceils themselves. Whether the tumor antigen is processed in some way by the tumor cells is not known. However, recognition of the tumor antigen by the CTL is most likely restricted by MHC class I determinants, since both proliferative and cytotoxic responses are inhibited by anti-CD8, but not anti-CD4, mAbs (our unpublished observations).
The anti-B10.5 CTL maintained long-term in medium containing IL-2 and IL-7 also express low levels of IL-2R.. Although the CTL do not require the addition of exogenous IL-2 to survive in vivo, it is clear that they require the presence of this cytokine to proliferate in response to tumor stimulator cells (Fig. 6) . Similar results have also been obtained using CTL maintained in IL-7 alone (data not shown). The data also demonstrate that the cells in these cultures endogenously produce sufficient quantities of IL-2 for this purpose. Thus, these CTL have become independent of the requirement for CD4 § helper cells to survive and function either in vitro or in vivo. Cells in these cultures also produce IFN-y in response to stimulation with tumor cells in vitro. However, preliminary studies indicate that IFN-y is not required for either proliferative or cytotoxic responses of these effector cells to tumors (data not shown). Whether the secretion of IFN-3' in vivo plays a significant role in tumor rejection is not known at this time.
The existence of helper-independent antitumor CTL has been described previously (37) . However, these cells not only required clonal activation before use, but also required ancillary IL-2 treatment of the recipients subsequent to adoptive transfer in order to demonstrate therapeutic efficacy (21) . Such manipulations were not required to demonstrate tumor elimination in vivo by the antitumor CTL described here.
Although no attempt was made to clone the tumor-reactive T cells in these experiments, it seems highly likely that a significant selection for such cells has occurred. In this regard, it is somewhat surprising that continued culture of heterogeneous starting populations of lymphoid cells containing antitumor CTL in medium containing IL-7 tended to favor the outgrowth of effector cells that retained the ability to mediate tumor rejection in vivo. This should not be construed to mean that IL-7 necessarily selects for cell lines which will function in vivo. A more likely explanation is that IL-7 promotes the survival and slow growth of specifically activated T cells, and a high proportion of antitumor CTL generated from DLN are capable of functioning in vivo.
The potential implications of the results of this study for the immunotherapeutic treatment of cancer may be significant. To date, most adoptive immunotherapy trials have focused on the generation of extremely large numbers of tumoricidal cells. Methods that have been used to achieve this goal have included intermittent stimulation of lymphoid cells obtained from hyperimmunized donors with tumor cells or tumor antigen (6, 37, 38) , nonspecific propagation with IL-2 (14-16), combinations of these two approaches (7) (8) (9) 20) , or nonspecific stimulation with Ab to CD3 in combination with IL-2 (39, 40) . Each of these approaches has attendant problems which have prevented them from being widely applicable to the immunotherapy of malignancy. For example, intermittent stimulation with tumor cells suffers from the problem that cells from spontaneously arising tumors are often difficult to propagate in vitro. Further, flesh tumors may contain infiltrating suppressor cells or may themselves produce suppressive factors (such as TGF-3). Expansion of tumoricidal lymphocytes with IL-2 (either alone or in combination with intermittent stimulation with tumor cells) tends to lead to the development ofT ceils dependent on exogenous IL-2 for continued growth and survival, both in vitro or in vivo (6, 38, 41) . Finally, tumor-reactive T cells propagated with anti-CD3 and IL-2 show progressive decreases in both in vitro and in vivo antitumor reactivity with repeated cycles of stimulation (38) . In contrast, the results of the studies presented here demonstrate that IL-7 promotes not only the propagation and maintenance of antitumor CTL for extended periods of time in vitro in the absence of repeated stimulation with either tumor cells or tumor antigen, but promotes the retention of in vivo function as well.
Data presented here demonstrate that antitumor CTL specific for tumors induced by either chronic exposure to UV irradiation (B10.5) or by the chemical carcinogen methylcholanthrene (B10.2) can be propagated in culture for extended periods of time using IL-7. In these experiments, we used antitumor CTL generated in vitro from the DLN of mice injected with viable syngeneic tumor cells. These cells were subsequently restimulated one time in vitro with irradiated tumor cells in medium containing IL-2, IL-7, or IL-2 and IL-7. However, the in vitro restimulation does not appear to be strictly required for the generation and maintenance of tumor-reactive cell lines since similar results have also been obtained using cultures of CTL generated from DLN in the absence of restimulation with tumor cells in vitro (our unpublished observations). Nor are the beneficial effects mediated by IL-7 necessarily limited to CD8 + T cells, since antigen-specific CD4 + cells have also been found to be maintained for extended periods of time (ca 12 too) in IL-7. It is also interesting to note that although short-term culture of heterogeneous populations oflymphocytes from both mouse and humans in IL-7 promotes the generation of LAK (42, 43) , such nonantigen-specific effector cells did not continue to proliferate in long-term cultures supplemented with IL-7. Indeed, after 4-5 wk of culture, only tumor-specific CTL continued to be maintained in cultures containing IL-7. The reasons for this phenomenon are not known, but have also been observed in populations of CTL maintained in IL-2 (38 and Fig. 1 ).
In conclusion, data presented here demonstrate that specific, antitumor CTL capable of mediating tumor rejection in vivo can be maintained in vitro for extended periods of time in the absence of repeated stimulation with irradiated tumor cells. Thus, with a continuously available source of antitumor effector cells, individuals with tumors could be treated (if need be) with several courses of CTL infusion. Further, with the increased specificity of the effector cell populations due to the absence of LAK activity, it seems likely that fewer cells might need to be infused compared with protocols currently in clinical use. Third, these cells can be cryogenically stored with no apparent loss in activity. Finally, such cells do not require the recipients to be treated with exogenous cytokines to promote or maintain function in vivo. Given the range of toxicities found to be caused by IL-2 administration in humans (44) , avoidance of IL-2 therapy might be beneficial. Since IL-7 promotes many, if not all, of the same biological activities in both mouse and human, the use of IL-7 to beneficially augment the generation and propagation of antitumor CTL may have profound implications for promoting the immunotherapeutic treatment of neoplasia in cancer patients.
